Multi-Center Phase IB/II Trial of Gemcitabine, Cisplatin, Plus Lenalidomide as First-Line Therapy for Patients with Metastatic Urothelial Carcinoma
ID Number 10-1339Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to find a safe dose of lenalidomide that can be given together with gemcitabine plus cisplatin. The purpose is also to find out what effects (good and bad) gemcitabine, cisplatin, and lenalidomide has on patients and their bladder (urothelial) carcinoma. This study will evaluate if adding lenalidomide to gemcitabine plus cisplatin may make gemcitabine plus cisplatin work better in treating cancer. Lenalidomide is approved by the Food and Drug Administration (FDA) for the treatment of certain blood cancers, but is not approved for the treatment of bladder (urothelial) cancer.
Patients may qualify to take part in this research study if they have been diagnosed as having advanced or metastatic bladder (urothelial) cancer, and they have not previously been treated with chemotherapy.
Recruiting Patients: Yes